Q4 2019 EPS Estimates for Charles River Laboratories Intl. Inc (NYSE:CRL) Decreased by Jefferies Financial Group

Charles River Laboratories Intl. Inc (NYSE:CRL) – Research analysts at Jefferies Financial Group lowered their Q4 2019 earnings per share (EPS) estimates for shares of Charles River Laboratories Intl. in a note issued to investors on Wednesday, November 6th. Jefferies Financial Group analyst D. Windley now expects that the medical research company will earn $1.82 per share for the quarter, down from their previous forecast of $1.83. Jefferies Financial Group also issued estimates for Charles River Laboratories Intl.’s Q2 2020 earnings at $1.81 EPS, Q3 2020 earnings at $1.87 EPS and FY2020 earnings at $7.35 EPS.

Several other equities research analysts have also issued reports on CRL. Bank of America lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “neutral” rating and set a $150.00 target price for the company. in a report on Friday, October 18th. Credit Suisse Group set a $138.00 target price on shares of Charles River Laboratories Intl. and gave the stock a “hold” rating in a report on Friday, September 13th. UBS Group lowered their target price on shares of Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating for the company in a report on Thursday. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Monday, October 21st. Finally, ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $150.31.

Shares of NYSE:CRL traded up $3.14 on Friday, reaching $130.51. The company’s stock had a trading volume of 320,134 shares, compared to its average volume of 360,739. The company has a 50-day simple moving average of $132.31 and a 200 day simple moving average of $133.44. The company has a market cap of $6.23 billion, a P/E ratio of 21.64, a PEG ratio of 2.00 and a beta of 1.08. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59. Charles River Laboratories Intl. has a 52-week low of $103.00 and a 52-week high of $149.07.

Charles River Laboratories Intl. (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $1.69 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.05. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The business had revenue of $668.00 million during the quarter, compared to analysts’ expectations of $674.08 million. During the same period last year, the company posted $1.53 EPS. The business’s revenue was up 14.1% on a year-over-year basis.

In related news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $130.36, for a total transaction of $162,819.64. Following the completion of the sale, the insider now owns 19,327 shares in the company, valued at approximately $2,519,467.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.80% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Squar Milner Financial Services LLC lifted its holdings in Charles River Laboratories Intl. by 253.2% during the 3rd quarter. Squar Milner Financial Services LLC now owns 219 shares of the medical research company’s stock valued at $28,000 after buying an additional 157 shares in the last quarter. Hussman Strategic Advisors Inc. bought a new stake in Charles River Laboratories Intl. during the 3rd quarter valued at about $33,000. Flagship Harbor Advisors LLC lifted its holdings in Charles River Laboratories Intl. by 132.1% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 318 shares of the medical research company’s stock valued at $45,000 after buying an additional 181 shares in the last quarter. CWM LLC lifted its holdings in Charles River Laboratories Intl. by 75.9% during the 3rd quarter. CWM LLC now owns 387 shares of the medical research company’s stock valued at $51,000 after buying an additional 167 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC bought a new stake in Charles River Laboratories Intl. during the 2nd quarter valued at about $69,000. Institutional investors own 94.31% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Recommended Story: What is the Dividend Aristocrat Index?

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.